Reece I J, Painvin G A, Chandler L B, Gentry B L, Zeluff B, Okereke O U, Cooley D A, Frazier O H
Transplantation Unit, Division of Surgery, the Cullen Cardiovascular Surgical Research Laboratories, and the Department of Infectious Diseases, Texas Heart Institute of St. Luke's Episcopal and Texas Children's Hospitals, Houston, Texas 77030, USA.
Tex Heart Inst J. 1984 Mar;11(1):32-7.
Since July 1982, 18 patients have undergone orthotopic cardiac transplantation at the Texas Heart Institute with steroid and cyclosporine immunosuppression. There have been no deaths from infection despite 15 bacterial, 8 viral, 6 fungal and 1 protozoal infection episodes. With a total follow-up of 90 patient months (mean follow-up, 5.0 months; range 0.1 to 18 months), the incidence of infection is 33 episodes per 100 patient months (1.7 episodes per patient). Only 23 episodes (77%) required drug treatment. Compared to conventional immunosuppressive regimes, cyclosporine treatment is associated with a substantial reduction in the incidence and severity of infection in cardiac allograft recipients.
自1982年7月以来,18例患者在德克萨斯心脏研究所接受了原位心脏移植,并采用了类固醇和环孢素免疫抑制治疗。尽管发生了15次细菌感染、8次病毒感染、6次真菌感染和1次原生动物感染,但没有患者因感染死亡。总随访时间为90个患者月(平均随访5.0个月;范围0.1至18个月),感染发生率为每100个患者月33次发作(每位患者1.7次发作)。只有23次发作(77%)需要药物治疗。与传统免疫抑制方案相比,环孢素治疗可使心脏移植受者的感染发生率和严重程度大幅降低。